CELZ
Price
$2.71
Change
-$0.01 (-0.37%)
Updated
Jul 25 closing price
Capitalization
6.99M
EDIT
Price
$3.15
Change
-$0.11 (-3.37%)
Updated
Jul 25 closing price
Capitalization
263.7M
3 days until earnings call
Interact to see
Advertisement

CELZ vs EDIT

Header iconCELZ vs EDIT Comparison
Open Charts CELZ vs EDITBanner chart's image
Creative Medical Technology Holdings
Price$2.71
Change-$0.01 (-0.37%)
Volume$100.45K
Capitalization6.99M
Editas Medicine
Price$3.15
Change-$0.11 (-3.37%)
Volume$1.28M
Capitalization263.7M
CELZ vs EDIT Comparison Chart in %
Loading...
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELZ vs. EDIT commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (CELZ: $2.71 vs. EDIT: $3.15)
Brand notoriety: CELZ and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELZ: 71% vs. EDIT: 49%
Market capitalization -- CELZ: $6.99M vs. EDIT: $263.7M
CELZ [@Biotechnology] is valued at $6.99M. EDIT’s [@Biotechnology] market capitalization is $263.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELZ’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CELZ’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CELZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELZ’s TA Score shows that 3 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • CELZ’s TA Score: 3 bullish, 5 bearish.
  • EDIT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than CELZ.

Price Growth

CELZ (@Biotechnology) experienced а -2.19% price change this week, while EDIT (@Biotechnology) price change was +14.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

CELZ is expected to report earnings on Aug 30, 2023.

EDIT is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($264M) has a higher market cap than CELZ($6.99M). EDIT YTD gains are higher at: 148.032 vs. CELZ (17.281). CELZ has higher annual earnings (EBITDA): -6.17M vs. EDIT (-244.52M). EDIT has more cash in the bank: 221M vs. CELZ (7.7M). CELZ has less debt than EDIT: CELZ (2.74M) vs EDIT (31.1M). EDIT has higher revenues than CELZ: EDIT (35.8M) vs CELZ (14K).
CELZEDITCELZ / EDIT
Capitalization6.99M264M3%
EBITDA-6.17M-244.52M3%
Gain YTD17.281148.03212%
P/E RatioN/AN/A-
Revenue14K35.8M0%
Total Cash7.7M221M3%
Total Debt2.74M31.1M9%
FUNDAMENTALS RATINGS
CELZ vs EDIT: Fundamental Ratings
CELZ
EDIT
OUTLOOK RATING
1..100
9590
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4936
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (44) in the Biotechnology industry is in the same range as CELZ (63) in the null industry. This means that EDIT’s stock grew similarly to CELZ’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELZ (100) in the null industry. This means that EDIT’s stock grew similarly to CELZ’s over the last 12 months.

CELZ's SMR Rating (97) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that CELZ’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as CELZ (49) in the null industry. This means that EDIT’s stock grew similarly to CELZ’s over the last 12 months.

CELZ's P/E Growth Rating (63) in the null industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that CELZ’s stock grew somewhat faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELZEDIT
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LCFY6.950.55
+8.59%
Locafy Limited
CHMI2.700.02
+0.75%
CHERRY HILL MORTGAGE INVESTMENT Corp
VSTS6.38N/A
N/A
Vestis Corp
GMAB23.40-0.23
-0.97%
Genmab A/S ADS
REAX4.14-0.06
-1.43%
Real Brokerage (The)